Oruka Therapeutics Quarterly Income Statement
NASDAQ: ORKAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
82.11+4.83 (+6.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Oruka Therapeutics revenue and earnings
Oruka Therapeutics reported a net loss of $41.2 million, compared with a loss of $24.6 million a year earlier.
Summary generated from market data by MetaCap's automated system. Methodology
Oruka Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q1 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | 50.11M | 36.43M | 34.43M | 34.10M | 28.43M | 25.09M | 29.45M | 21.49M | 2.48M | 1.59M | 1.94M | 1.97M |
| Research & Development | 43.26M | 29.14M | 27.64M | 28.99M | 24.09M | 19.93M | 25.69M | 18.67M | 165.00K | 47.00K | 322.00K | 254.00K |
| Operating Income | -50.11M | -36.43M | -34.43M | -34.10M | -28.43M | -25.09M | -29.45M | -21.49M | -2.48M | -1.59M | -1.94M | -1.97M |
| Interest Expense | — | — | — | — | — | — | 504.00K | 750.00K | — | — | — | — |
| Other Income (Expense) | 8.90M | 4.61M | 4.85M | 3.83M | 3.85M | 4.09M | 826.00K | -750.00K | — | — | — | — |
| Net Income | -41.21M | -31.82M | -29.58M | -30.28M | -24.57M | -21.00M | -28.62M | -22.24M | -2.01M | -1.09M | -1.42M | -1.48M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | — | — | -0.46 | -0.40 | -1.46 | -6.96 | -0.14 | -0.08 | -0.10 | -0.10 |
| EPS (Diluted) | — | — | — | — | -0.46 | -0.40 | -1.46 | -6.96 | -0.14 | -0.08 | -0.10 | -0.10 |
| Shares Outstanding (Basic) | — | — | — | — | 42.10M | 41.68M | 15.01M | 3.20M | 14.50M | — | 14.41M | 14.41M |
| Shares Outstanding (Diluted) | — | — | — | — | 42.10M | 41.68M | 15.01M | 3.20M | 14.50M | — | 14.41M | 14.41M |
| EBITDA | -50.06M | -36.39M | -34.40M | -34.09M | -28.41M | -25.07M | — | -21.49M | -2.48M | -1.59M | -1.93M | -1.97M |
This table shows 12 quarterly periods of Oruka Therapeutics's income statement, from Q2 2026 back to Q1 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ORKA's reporting calendar. What is a income statement?